HlatkyMA.
What we can learn from a decision model: comment on
“Cost-effectiveness of adding magnetic resonance imaging to rheumatoid
arthritis management”. Arch Intern Med.
2011;171:667–8.
2.
PignoneMRansohoffDF.
Cross-modelcomparisons to improve the value of modeling: the case of colorectal
cancer screening. Med Decis Making.
2011;31(4):524–526.
3.
MandelblattJSCroninKABaileyS,
for the Breast Cancer Working Group of the
Cancer Intervention and Surveillance Modeling Network (CISNET).
Effects of mammography screening under different screening
schedules: model estimates of potential benefits and harms.
Ann Intern Med.
2009;151:738–47.
4.
WeverEMDraismaGHeijnsdijkEAMde
KoningHJ.
How does early detection by screening affect disease
progression? Modeling estimated benefits in prostate cancer
screening. Med Decis Making.
2011;31(4):550–558.
5.
van
BallegooijenMRutterCMKnudsenAB.
Clarifying differences in natural history between models of
screening: the case of colorectal cancer. Med Decis
Making.
2011;31(4):540–549
6.
EssermanLShiehYThompsonI.
Rethinking screening for breast cancer and prostate
cancer. JAMA.
2009;302:1685–92.
7.
ErenayFSAlagozOBanerjeeRCimaRR.
Estimating the unknown parameters of the natural history of
metachronous colorectal cancer using discrete-event
simulation. Med Decis Making.
2011;31(4):611–624.
8.
WhyteSWalshCChilcottJ.
Bayesian calibration of a natural history model with
application to a population model for colorectal cancer.
Med Decis Making.
2011;31(4):625–641.
9.
DysonF.
Origins of Life. Cambridge,
UK: Cambridge University
Press; 1985.
10.
JacksonCHBojkeLThompsonSGClaxtonKSharplesLD.
A framework for addressing structural uncertainty in decision
models. Med Decis Making.
2011;31(4):662–674.
